Access Biotechnology
Growth equityNew York City Β· SeedβLate Stage Β· 2 people tracked
Investment thesis
Access Biotechnology believes that sustainable financial returns stem from fundamental value creation in the development of novel medicines that meaningfully impact patient health and society. The firm leverages deep medical and scientific expertise to evaluate opportunities rigorously, supports portfolio companies through long-term holding periods unconstrained by typical venture fund cycles, and partners collaboratively with founders and fellow investors to build companies advancing important therapeutic innovations across diverse disease areas.
Source: firm website, verified Aug 5, 2026.
Team Β· 2 people
from the firm's website & public directories
What they invest in
from 8 of 29 portfolio companiesBiotech Γ8Medical Devices Γ3Digital Health Γ1
HQs:United StatesΓ9
Investments Β· 29 tracked
founders shown can be your intro pathArvinas is a clinical-stage biopharmaceutical company developing PROTAC protein degrader therapies for oncology and neurology.
BiotechNew Haven, US
Stephen Squinto(Director)Liam Ratcliffe(Director)Andrew Levin(Director)Sean Cassidy(Executive Officer)Jonathan Soderstrom(Director)Brad Margus(Director)
Advancing potentially best-in-class therapeutics for myeloproliferative neoplasms.
Copenhagen, US
OnKure discovers and develops precision medicines targeting specific cancer drivers and vascular anomalies using structure-based drug design.
BiotechDigital HealthMedical DevicesBoulder, US
Jason Leverone(Executive Officer)Samuel Agresta(Executive Officer)Dylan Hartley(Executive Officer)Nicholas Saccomano(Executive Officer, Director)Scott Weiner(Director)Wendy Johnson(Executive Officer)
Novartis is a pharmaceutical company with a history spanning 250 years of scientific innovation.
BiotechSan Diego, US
Arthur T Suckow(Executive Officer)
BiotechMedical DevicesNew Haven, US
Scott Phillips(Executive Officer)Tim Shannon(Manager)Liam Ratcliffe(Manager)Leyi Wang(Manager)Rebecca Frey(Manager)
Discovering precision small molecule medicines that harness the power of covalency to transform the treatment of immune diseases.
Harnesses cutting-edge technologies to design exquisitely selective small molecule therapeutics.
BiotechCambridge, US
Vikas Goyal(Director)Jo Viney(Executive Officer)Mitchell Mutz(Director)Carlo Rizzuto(Director)Alan Crane(Director)Anthony Coyle(Executive Officer, Director)
San Francisco, US
Chau Khuong(Director)Sevgi Gurkan(Executive Officer, Director, Promoter)
BoardChristy Shaffer(Director)
BiotechSouth San Francisco, US
MARTIN BABLER(Executive Officer, Director)PETER THOMPSON(Director)SRINIVAS AKKARAJU(Director)LEWIS J. SHUSTER(Director)MICHAEL DYBBS(Director)SIMEON GEORGE(Director)
Santa Ana Bio develops engineered antibodies targeting immune system pathways to treat autoimmune and inflammatory diseases.
BiotechMedical DevicesAlameda, US
Peter Emtage(Founder & CEO)inAlexander Rudensky(Scientific Founder)Richard Flavell(Scientific Founder)Graham Lord(Scientific Founder)Ansuman Satpathy(Scientific Founder)Thomas Woiwode(Director)
Developing potential best-in-class bispecific antibody therapeutics for immunologic diseases.
BiotechLondon
Jan-Anders Karlsson(Executive Officer, Director)David Ebsworth(Director)Patrick Humphrey(Director)Peter Spargo(Executive Officer)Ken Cunningham(Director)Kenneth Newman(Executive Officer)
Frequently asked questions
- What stage does Access Biotechnology invest at?
- Access Biotechnology invests at the Seed, Series A, Series B, Growth, Late Stage stages.
- What sectors does Access Biotechnology focus on?
- Access Biotechnology focuses on Biotech.
- Where is Access Biotechnology located?
- Access Biotechnology is headquartered in New York City, US.
- Does Access Biotechnology lead rounds?
- Yes, Access Biotechnology leads investment rounds.
Images
Co-investors Β· 5
Andreessen Horowitz's Strategic Partnerships page describes collaborations that connect its portfolio companies with established institutions to help scale and deploy their technology.
GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning companies since its early days, building a global portfolio spanning AI infrastructure, life sciences, and applications.
Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.
Access Industries is a private holding company and global investment firm founded in 1986 by Len Blavatnik that identifies companies with strong business models and management teams to optimize their value through financial backing and strategic expertise.
Amzak Health is a venture investor focused on first-in-class and best-in-class technologies in the medtech and biotech sectors, partnering closely with portfolio company management teams.
Firms observed investing alongside Access Biotechnology, from public investor directories.
Similar investors
Quadrille is an independent investment manager focused on venture capital and growth equity, investing globally in technology and healthcare assets.
Corner Ventures is a venture capital firm that invests in technology companies at key development stages.
Northstar Ventures is a UK venture capital firm based in the north of England that invests in early and later stage high-growth companies tackling global challenges, with a focus on climate tech and healthy ageing.
Fluke Venture Partners is a Pacific Northwest venture firm that has funded technology, healthcare, and consumer companies for over three decades, working with management teams as long-term partners from early stages onward.
Roadmap Capital Inc. is an investment platform providing co-investment access to private companies in technology and healthcare/medtech sectors.